Scandinavian ChemoTech - Updates from our animal care unit
Dr Omar Maher, an internationally renowned equestrian veterinarian, at the Atlantic Equine Services in Florida, performed his first TSE (Tumour Specific Electroporation™) treatment which targeted a large sarcoid on the hind leg. The TSE treatment was done under standing sedation, and we have already received a report that the sarcoid has completely fallen off.
Another clinic in Florida has placed their first order of treatment kits. This small animal clinic is specialising in pet cancer and is led by a board-certified veterinary oncologist with over 10 years’ experience in the field. The oncologist is at the forefront of animal cancer therapy. This makes the third installation in the US.
In Australia, the Agnes Banks Equine Clinic and Apiam Animal Health has performed their first TSE treatment on an equine sarcoid. This was the first patient in a case series study. The treatment was performed under standing sedation with the support and supervision of our distributor Gamma Gurus and our own staff (via link).
“vetIQure™ is a perfect first treatment modality for multiple soft tissue cancers such as sarcoids, melanoma and mast cell tumours, particularly when surgical margins cannot be secured or are cosmetically challenging. We are looking forward to some further treatments on small animals over the next few weeks”, says Gerrie Beirne, Sales and Marketing guru for Gamma Gurus.
Vetiqure also reports a continued strong support from veterinarians in transferring the knowledge of vetIQure and its TSE technology at exhibitions. At the upcoming ESVONC conference in Alicante, we have the privilege to have Silvia Janska demonstrating with us in our booth. Silvia has also played a big part in our ongoing dialogue with RVC and works as an equine vet and animal health business consultant.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
